Development of an MCT1/4 dual inhibitor as an anti-cancer drug

• Forschungsstelle: INNOSUISSE
• Projektnummer: 103.872 IP-LS
• Projekttitel Englisch: Development of an MCT1/4 dual inhibitor as an anti-cancer drug

Schlüsselwörter (Englisch)

Life sciences, Pharmaceuticals

Abstract (Englisch)

The lactate transporters MCT1 and MCT4 are validated cancer drug targets. No MCT4 inhibitor has entered clinical testing. We have developed a drug series with dual MCT1 and MCT4 inhibition. We aim to further develop this series to improve efficacy, IP position and drug-like properties.